8002 ORAL Front-line Bevacizumab (BEV) Combined With Weekly Paclitaxel (wPAC) and Carboplatin (C) for Ovarian Cancer (OC): Safety Results From the Concurrent Chemotherapy (CT) Phase of the OCTAVIa Study